Table 1.
PPPM all-cause and treatment-related grade 3/4 AE costs in CheckMate 9ER
| N+C (N = 320) | SUN (N = 320) | Difference (SUN − N+C) | P value | |||||
|---|---|---|---|---|---|---|---|---|
| Total grade 3/4 AE costs | Patient-months | PPPM grade 3/4 AE costs | Total grade 3/4 AE costs | Patient-months | PPPM grade 3/4 AE costs | |||
| All-cause grade 3/4 AEs over | ||||||||
| 3 months | $1,896,980 | 938.7 | $2021 | $2,794,959 | 902.5 | $3097 | $1076 | < 0.05* |
| 6 months | $2,979,559 | 1802.2 | $1653 | $3,843,536 | 1589.6 | $2418 | $765 | < 0.05* |
| 12 months | $4,740,289 | 3269.8 | $1450 | $5,015,224 | 2592.0 | $1935 | $485 | 0.0575 |
| 18 months | $5,531,528 | 4135.7 | $1337 | $5,420,683 | 3088.5 | $1755 | $418 | 0.0952 |
| Treatment-related grade 3/4 AEs over | ||||||||
| 3 months | $1,410,645 | 938.7 | $1503 | $1,771,166 | 902.5 | $1963 | $460 | 0.3224 |
| 6 months | $2,184,036 | 1802.2 | $1212 | $2,517,873 | 1589.6 | $1584 | $372 | 0.6096 |
| 12 months | $3,201,823 | 3569.8 | $979 | $3,246,695 | 2592.0 | $1253 | $274 | 0.8995 |
| 18 months | $3,557,610 | 4135.7 | $860 | $3,561,377 | 3088.5 | $1153 | $293 | 0.7479 |
Analyses were conducted among patients in the as-treated population who received at least 1 dose of the study drug in CheckMate 9ER. Statistical comparisons of PPPM AE costs between N+C and SUN were conducted using Wilcoxon rank-sum tests
AE adverse event, N+C nivolumab plus cabozantinib, PPPM per-patient-per-month, SUN sunitinib
*Statistically significant at the 5% level